HUTCHMED licenses HMPL-A830, a KRAS-EGFR antibody-targeted therapy, to GSK in a deal worth up to $1.295 billion, with Phase 1 trials expected in H2 2026.
Written By: Siddhi Bhadekar, M. Pharm (QA)
Reviewed By: Pharmacally Editorial Team
HUTCHMED Limited has entered an exclusive development and license agreement with a GSK subsidiary for HMPL-A830. The deal includes a $110 million upfront payment, up to $1.185 billion in additional development, regulatory, and commercial milestones, and tiered royalties on net sales, giving the agreement a potential value of $1.295 billion.
HUTCHMED will retain full development and commercialization rights in Mainland China, Hong Kong, Macau, and Taiwan. It will also remain responsible for the global Phase 1 development program, expected to begin in the second half of 2026 under clinical trial NCT07718581. GSK will assume responsibility for subsequent clinical development and commercialization outside the retained territories.
The agreement is subject to customary closing conditions, including completion of applicable antitrust reviews. The upfront payment is payable at closing.
Dual Targeting of KRAS and EGFR
HMPL-A830 combines a highly selective KRAS small-molecule inhibitor payload with an anti-EGFR antibody. The ATTC platform uses antibody-guided delivery to direct the KRAS inhibitor toward EGFR-expressing tumor cells.
The approach is intended to combine two complementary mechanisms: KRAS inhibition within tumor cells and EGFR blockade at the cell surface. Both pathways feed into downstream signaling networks, including RAS/MAPK and PI3K/AKT/mTOR, which regulate tumor-cell proliferation and survival.
The strategy addresses limitations associated with systemic KRAS inhibition. Although KRAS has become a validated oncology target, treatment options remain limited for many KRAS-altered tumors, and acquired resistance can reduce the durability of responses. Systemic inhibition of RAS pathway signaling can also cause on-target toxicities in normal tissues, potentially constraining dosing and long-term treatment.
While approved KRAS inhibitors such as sotorasib and adagrasib specifically target the KRAS G12C variant, HMPL-A830 combines an EGFR-targeting antibody with a KRAS inhibitor payload. HUTCHMED’s announcement does not specify the particular KRAS variant targeted by the payload.
EGFR also has a strong biological rationale in colorectal cancer, where increased upstream EGFR signaling can reactivate the MAPK pathway and contribute to resistance to KRAS-directed therapies.
Initial Development in Three Major Cancers
Clinical development will initially focus on colorectal cancer, pancreatic cancer, and lung cancer, which include a substantial proportion of KRAS-driven tumors.
According to HUTCHMED, KRAS mutations occur in approximately 44% of colorectal cancers, 34% of lung adenocarcinomas, and up to 89% of pancreatic ductal adenocarcinomas. These cancers therefore represent significant areas of unmet need, particularly for patients whose tumors lack effective targeted treatment options.
No clinical efficacy or safety data for HMPL-A830 have yet been reported. The planned Phase 1 study will establish the candidate’s initial safety, tolerability, pharmacokinetic profile, and appropriate dosing while providing the first human clinical data for the program.
GSK Takes Global Development Role
Johnny Cheng, HUTCHMED’s acting CEO and CFO, said the agreement marks the first licensing deal for a drug candidate from the company’s ATTC platform with a global partner. Two other candidates from the company’s proprietary payload platforms have already entered clinical development.
GSK’s oncology leadership highlighted the potential of simultaneously targeting KRAS and EGFR, particularly given the role of upstream signaling in resistance to KRAS-directed therapies.
The transaction also gives GSK a right of first negotiation on one earlier-stage ATTC drug candidate, expanding the potential scope of the collaboration beyond HMPL-A830.
Phase 1 Start Expected in H2 2026
HUTCHMED will conduct the global Phase 1 program, with clinical development expected to begin in the second half of 2026. Following the initial program, GSK will take responsibility for development and commercialization outside Mainland China, Hong Kong, Macau, and Taiwan.
The first clinical results will be important for determining whether HMPL-A830 can translate its tumor-targeted delivery approach into a clinically meaningful safety and efficacy profile. For now, the transaction represents a significant validation of HUTCHMED’s ATTC platform while giving GSK access to an early-stage approach that combines EGFR targeting with KRAS inhibition.
Reference
About the Writer
Siddhi Rajendra Bhadekar (Linkedin) is an M.Pharm professional with expertise in medical and scientific writing, literature review, publication writing, and evidence synthesis, supported by four peer-reviewed publications.
She brings working knowledge of ICH-GCP, MedDRA, pharmacovigilance, ADR/AE reporting, clinical data management, and regulatory documentation.
With experience across pharmaceutical R&D, Quality Control, and Quality Assurance, she combines scientific research skills with strong attention to accuracy and detail.
Her background in manuscript development, publication planning, and scientific communication enables her to translate complex healthcare information into clear, reliable content.